Mitsi A. Blount

High lung PDE5: A strong basis for treating pulmonary hypertension with PDE5 inhibitors

Jackie D. Corbin, Alfreda Beasley, Mitsi A. Blount et al. · Biochemical and Biophysical Research Communications · 2005 · 200 citations

Hypertension, Pulmonary Arterial Hypertension, Pulmonary Circulation +11

Binding of Tritiated Sildenafil, Tadalafil, or Vardenafil to the Phosphodiesterase-5 Catalytic Site Displays Potency, Specificity, Heterogeneity, and cGMP Stimulation

Mitsi A. Blount, Alfreda Beasley, Roya Zoraghi et al. · Molecular Pharmacology · 2004 · 174 citations

miR-23a is decreased during muscle atrophy by a mechanism that includes calcineurin signaling and exosome-mediated export

Matthew B. Hudson, Myra E. Woodworth‐Hobbs, Bin Zheng et al. · American Journal of Physiology-Cell Physiology · 2013 · 129 citations · Full text

Muscle Function, Engineering, Skeletal Muscle Atrophy +18

Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5)

Jackie D. Corbin, Alfreda Beasley, Mitsi A. Blount et al. · Neurochemistry International · 2004 · 87 citations

Molecular Pharmacology, Medicinal Chemistry, Higher Potency +6

Phosphorylation of UT-A1 urea transporter at serines 486 and 499 is important for vasopressin-regulated activity and membrane accumulation

Mitsi A. Blount, Abinash C. Mistry, Otto Fröhlich et al. · American Journal of Physiology-Renal Physiology · 2008 · 86 citations · Full text

Protein Secretion, Membrane Accumulation, Serines 486 +20